

Doruk Erkan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/463495/publications.pdf>

Version: 2024-02-01

84
papers

4,653
citations

136950

32
h-index

102487

66
g-index

89
all docs

89
docs citations

89
times ranked

3628
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2022, 21, 102913.	5.8	13
2	Defibrotide Inhibits Antiphospholipid Antibody-Mediated Neutrophil Extracellular Trap Formation and Venous Thrombosis. <i>Arthritis and Rheumatology</i> , 2022, 74, 902-907.	5.6	19
3	Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the CAPS Registry. <i>Autoimmunity Reviews</i> , 2022, 21, 103055.	5.8	34
4	The clinical significance of low complement levels in patients with catastrophic antiphospholipid syndrome: A descriptive analysis of 73 patients from the Catastrophic antiphospholipid syndrome registry. <i>Lupus</i> , 2022, 31, 1218-1225.	1.6	4
5	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1490-1501.	3.4	60
6	Reality Check on Antiphospholipid Antibodies in COVID-19 Associated Coagulopathy. <i>Arthritis and Rheumatology</i> , 2021, 73, 173-174.	5.6	39
7	A Covid-19 Patient with Complement-Mediated Coagulopathy and Severe Thrombosis. <i>Pathobiology</i> , 2021, 88, 28-36.	3.8	15
8	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021, 48, 541-547.	2.0	19
9	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. <i>Current Rheumatology Reports</i> , 2021, 23, 45.	4.7	9
10	16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2021, 30, 1314-1326.	1.6	9
11	A critical analysis of 57 cases of Hughes-Stovin syndrome (HSS). A report by the HSS International Study Group (HSSISG). <i>International Journal of Cardiology</i> , 2021, 331, 221-229.	1.7	18
12	Pulmonary vasculitis in Hughes-Stovin syndrome (HSS): a reference atlas and computed tomography pulmonary angiography guide—a report by the HSS International Study Group. <i>Clinical Rheumatology</i> , 2021, 40, 4993-5008.	2.2	9
13	Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Advances in Rheumatology</i> , 2021, 61, 64.	1.7	0
14	1504...The influence of dietary resistant starch content on the gut microbiota of patients with systemic lupus erythematosus and antiphospholipid syndrome. , 2021, , .		0
15	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION). <i>Lupus</i> , 2021, 30, 2276-2285.	1.6	21
16	Recurrent Complement-Mediated Thrombotic Microangiopathy in a Patient with Systemic Lupus Erythematosus. <i>HSS Journal</i> , 2020, 16, 507-514.	1.7	0
17	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020, 29, 1353-1363.	1.6	28
18	Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. <i>Nature Reviews Rheumatology</i> , 2020, 16, 581-589.	8.0	203

#	ARTICLE	IF	CITATIONS
19	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	1.6	80
20	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2828-2839.	3.8	211
21	16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. <i>Lupus</i> , 2020, 29, 1594-1600.	1.6	26
22	Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2274-2286.	3.8	24
23	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2069-2080.	3.8	9
24	Pathogenic Autoreactive T and B Cells Cross-React with Mimotopes Expressed by a Common Human Gut Commensal to Trigger Autoimmunity. <i>Cell Host and Microbe</i> , 2019, 26, 100-113.e8.	11.0	109
25	Clinical Insights into Diffuse Alveolar Hemorrhage in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2019, 21, 56.	4.7	20
26	Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 102395.	5.8	35
27	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019, 175, 32-36.	1.7	13
28	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 464-468.	3.4	79
29	Is there a role for immunosuppression in antiphospholipid syndrome?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 426-432.	2.5	22
30	Treatment of antiphospholipid syndrome beyond anticoagulation. <i>Clinical Immunology</i> , 2019, 206, 53-62.	3.2	23
31	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019, 71, 134-141.	3.4	37
32	Impact of antiphospholipid syndrome iBook on medical students'™ improvement of knowledge: An international randomized controlled study. <i>European Journal of Rheumatology</i> , 2019, 6, 207-211.	0.6	1
33	The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. <i>Rheumatology</i> , 2018, 57, 1264-1270.	1.9	70
34	Variants in chondroitin sulfate metabolism genes in thrombotic storm. <i>Thrombosis Research</i> , 2018, 161, 43-51.	1.7	5
35	Diagnosis and Management of the Antiphospholipid Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 1289-1290.	27.0	51
36	Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?. <i>Current Rheumatology Reports</i> , 2018, 20, 66.	4.7	16

#	ARTICLE	IF	CITATIONS
37	Diagnosis and Management of the Antiphospholipid Syndrome. <i>New England Journal of Medicine</i> , 2018, 378, 2010-2021.	27.0	503
38	Infodemiology of antiphospholipid syndrome: Merging informatics and epidemiology. <i>European Journal of Rheumatology</i> , 2018, 5, 92-95.	0.6	14
39	Catastrophic Antiphospholipid Syndrome: Candidate Therapies for a Potentially Lethal Disease. <i>Annual Review of Medicine</i> , 2017, 68, 287-296.	12.2	23
40	Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2017, 16, 576-586.	5.8	48
41	Comment on: "The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome". <i>Thrombosis Research</i> , 2017, 157, 82-83.	1.7	5
42	Immunoglobulin G4-related Aortitis. <i>HSS Journal</i> , 2017, 13, 307-312.	1.7	2
43	Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus Patients. <i>Arthritis Care and Research</i> , 2017, 69, 1209-1216.	3.4	11
44	Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. <i>Blood Advances</i> , 2017, 1, 2320-2324.	5.2	40
45	The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. <i>European Journal of Rheumatology</i> , 2016, 3, 75-84.	0.6	141
46	Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. <i>Autoimmunity Reviews</i> , 2016, 15, 1120-1124.	5.8	211
47	AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update. <i>Current Rheumatology Reports</i> , 2016, 18, 64.	4.7	12
48	Miscellaneous inflammatory musculoskeletal conditions: Always a diagnostic and therapeutic challenge. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 221.	3.3	0
49	Mitral Valve Vegetation in Antiphospholipid Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 1300-1300.	5.6	1
50	Thromboelastography in the Characterization of Coagulation Status in Antiphospholipid Syndrome. <i>Blood</i> , 2016, 128, 4983-4983.	1.4	5
51	The Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome. <i>Turkish Journal of Haematology</i> , 2016, 33, 1-7.	0.5	38
52	Recurrent Thrombosis in Patients with Antiphospholipid Antibodies and Arterial Thrombosis Treated with Antiplatelets and/or Anticoagulant Therapy. <i>Blood</i> , 2016, 128, 86-86.	1.4	0
53	How I treat catastrophic thrombotic syndromes. <i>Blood</i> , 2015, 126, 1285-1293.	1.4	58
54	Patients with overlap autoimmune disease differ from those with 'pure' disease. <i>Lupus Science and Medicine</i> , 2015, 2, e000084-e000084.	2.7	28

#	ARTICLE	IF	CITATIONS
55	The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2028-2033.	0.9	124
56	Rapidly Progressive Cardiac Failure Due to Giant Cell Myocarditis. <i>HSS Journal</i> , 2015, 11, 182-186.	1.7	2
57	Antiphospholipid syndrome research needs more collaboration. <i>Nature Reviews Rheumatology</i> , 2014, 10, 266-267.	8.0	2
58	Lepromatous Leprosy Mimicking Systemic Lupus Erythematosus. <i>HSS Journal</i> , 2014, 10, 286-291.	1.7	12
59	A106: Rituximab Use in Pediatric Antiphospholipid Antibody Positive Patients. <i>Arthritis and Rheumatology</i> , 2014, 66, S142-S142.	5.6	1
60	A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1176-1180.	0.9	106
61	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. <i>Autoimmunity Reviews</i> , 2014, 13, 281-291.	5.8	166
62	14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Autoimmunity Reviews</i> , 2014, 13, 685-696.	5.8	290
63	Rare Manifestation of Granulomatosis With Polyangiitis. <i>Clinical Advances in Periodontics</i> , 2013, 3, 45-50.	0.7	0
64	Estimated Frequency of Antiphospholipid Antibodies in Patients With Pregnancy Morbidity, Stroke, Myocardial Infarction, and Deep Vein Thrombosis: A Critical Review of the Literature. <i>Arthritis Care and Research</i> , 2013, 65, 1869-1873.	3.4	275
65	Systemic Lupus Erythematosus Associated with Rowell's Syndrome. <i>HSS Journal</i> , 2013, 9, 289-292.	1.7	8
66	Cognitive dysfunction and white matter abnormalities in antiphospholipid syndrome. <i>Pathophysiology</i> , 2011, 18, 93-102.	2.2	19
67	Whole-Exome Sequencing Identifies Novel Risk Variant for Thrombotic Storm. <i>Blood</i> , 2011, 118, 1229-1229.	1.4	0
68	Catastrophic antiphospholipid syndrome: Updated diagnostic algorithms. <i>Autoimmunity Reviews</i> , 2010, 10, 74-79.	5.8	152
69	New approaches for managing antiphospholipid syndrome. <i>Nature Reviews Rheumatology</i> , 2009, 5, 160-170.	8.0	58
70	Elevated Levels of Cytokines and Chemokines in Patients with Antiphospholipid (aPL) Antibodies.. <i>Blood</i> , 2009, 114, 5062-5062.	1.4	6
71	Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibodyâ€“positive individuals. <i>Arthritis and Rheumatism</i> , 2007, 56, 2382-2391.	6.7	364
72	New Treatments for Antiphospholipid Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 129-148.	1.9	32

#	ARTICLE	IF	CITATIONS
73	Antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2006, 18, 242-248.	4.3	25
74	Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2006, 6, 98-103.	5.8	50
75	What is antiphospholipid syndrome?. <i>Current Rheumatology Reports</i> , 2004, 6, 451-457.	4.7	42
76	How much warfarin is enough in APS related thrombosis?. <i>Thrombosis Research</i> , 2004, 114, 435-442.	1.7	13
77	New insights into pregnancy-related complications in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2003, 5, 357-363.	4.7	16
78	Catastrophic antiphospholipid syndrome: Where do we stand?. <i>Arthritis and Rheumatism</i> , 2003, 48, 3320-3327.	6.7	100
79	Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: The impact of cost on first-line therapy. <i>Arthritis and Rheumatism</i> , 2002, 47, 285-290.	6.7	24
80	The relation between antiphospholipid syndrome-related pregnancy morbidity and non-gravid vascular thrombosis: A review of the literature and management strategies. <i>Current Rheumatology Reports</i> , 2002, 4, 379-386.	4.7	17
81	Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. <i>Journal of Rheumatology</i> , 2002, 29, 843-9.	2.0	77
82	The role of cardiac magnetic resonance imaging in antiphospholipid syndrome. <i>Journal of Rheumatology</i> , 2002, 29, 2658-9.	2.0	6
83	High thrombosis rate after fetal loss in antiphospholipid syndrome: Effective prophylaxis with aspirin. <i>Arthritis and Rheumatism</i> , 2001, 44, 1466-1467.	6.7	187
84	High thrombosis rate after fetal loss in antiphospholipid syndrome: Effective prophylaxis with aspirin. , 2001, 44, 1466.		1